Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Chen, Robert; Zinzani, Pier Luigi; Fanale, Michelle A.; Armand, Philippe; Johnson, Nathalie A.; Brice, Pauline; Radford, John; Ribrag, Vincent; Molin, Daniel; Vassilakopoulos, Theodoros P.; Tomita, Akihiro; Tresckow, Bastian von; Shipp, Margaret A.; Zhang, Yinghua; Ricart, Alejandro D.; Balakumaran, Arun; Moskowitz, Craig H.; KEYNOTE-087, for the

doi:10.1200/jco.2016.72.1316

articleJournal of Clinical OncologyApr 25, 2017GREEN OA

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

RCRobert Chen PLPier Luigi Zinzani MAMichelle A. Fanale PAPhilippe Armand NANathalie A. Johnson

City Of Hope National Medical Center · Novartis (Switzerland) · +6 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of…

Citation impact

978

total citations

FWCI: 99.87
Percentile: 100%
References: 16

Citations per year

Authors

18

Topics & keywords

Topics

Keywords

Pembrolizumab
Medicine
Cohort
Brentuximab vedotin
Internal medicine
Oncology
Autologous stem-cell transplantation
Transplantation

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.